We anticipate further successes from this innovative alliance based on outstanding research and an extremely close romantic relationship between Evotec and Boehringer Ingelheim’s scientists.’.. Achievement of tenth milestone triggers EUR 2.5 million payment from Boehringer Ingelheim to Evotec Evotec AG today declared that its research alliance with Boehringer Ingelheim has reached a milestone, triggering a payment of EUR 2.5 million to Evotec. The milestone reached was the selection of a candidate compound for pre-development studies within an immunology and inflammation programme. Dr. Werner Lanthaler, CEO of Evotec, commented: ‘This is actually the tenth milestone achieved since the inception of the collaboration between Boehringer Ingelheim and Evotec in 2004, therefore underlining the great success of one of the largest and most significant global study alliances between pharma and biotech.0.69,>Significant differences between REM and LDA weren’t seen in the domain of %age impairment while working and 66 sufferers achieving LDA (2.. A serpiginous burrow on the foot A man presents with pruritic, serpiginous cords about his left feet. What are these lesions and how as long as they be treated? After a beach holiday in Thailand, a 23-year-old guy developed pruritic, serpiginous cords on the sole and medial aspect of his left foot . The cords had commenced with an itchy papule, which over the following three weeks shaped an erratic intersecting design with focal areas that were eroded, crusted, pustular or haemorrhagic. A skin biopsy demonstrated subepidermal and intraepidermal blisters with eosinophils that prolonged diffusely into the underlying dermis and subcutis .